Jilin University

About: Jilin University is a education organization based out in Changchun, China. It is known for research contribution in the topics: Catalysis & Apoptosis. The organization has 101453 authors who have published 88966 publications receiving 1444456 citations. The organization is also known as: Jílín Dàxué.

Route to a Superconducting Phase above Room Temperature in Electron-Doped Hydride Compounds under High Pressure

Abstract: The recent theory-orientated discovery of record high-temperature superconductivity (T_{c}∼250 K) in sodalitelike clathrate LaH_{10} is an important advance toward room-temperature superconductors. Here, we identify an alternative clathrate structure in ternary Li_{2}MgH_{16} with a remarkably high estimated T_{c} of ∼473 K at 250 GPa, which may allow us to obtain room-temperature or even higher-temperature superconductivity. The ternary compound mimics a Li- or electron-doped binary hydride of MgH_{16}. The parent hydride contains H_{2} molecules and is not a good superconductor. The extra electrons introduced break up the H_{2} molecules, increasing the amount of atomic hydrogen compared with the parent hydride, which is necessary for stabilizing the clathrate structure or other high-T_{c} structures. Our results provide a viable strategy for tuning the superconductivity of hydrogen-rich hydrides by donating electrons to hydrides via metal doping. Our approach may pave the way for finding high-T_{c} superconductors in a variety of ternary or quaternary hydrides.

Zeolite‐Encaged Single‐Atom Rhodium Catalysts: Highly‐Efficient Hydrogen Generation and Shape‐Selective Tandem Hydrogenation of Nitroarenes

Abstract: Single-atom catalysts are emerging as a new frontier in heterogeneous catalysis because of their maximum atom utilization efficiency, but they usually suffer from inferior stability. Herein, we synthesized single-atom Rh catalysts embedded in MFI-type zeolites under hydrothermal conditions and subsequent ligand-protected direct H-2 reduction. C-s-corrected scanning transmission electron microscopy and extended X-ray absorption analyses revealed that single Rh atoms were encapsulated within 5-membered rings and stabilized by zeolite framework oxygen atoms. The resultant catalysts exhibited excellent H-2 generation rates from ammonia borane (AB) hydrolysis, up to 699 min(-1) at 298 K, representing the top level among heterogeneous catalysts for AB hydrolysis. The catalysts also showed superior catalytic performance in shape-selective tandem hydrogenation of various nitroarenes by coupling with AB hydrolysis, giving >99 % yield of corresponding amine products.

Bioinspired Diselenide-Bridged Mesoporous Silica Nanoparticles for Dual-Responsive Protein Delivery.

Abstract: Controlled delivery of protein therapeutics remains a challenge. Here, the inclusion of diselenide-bond-containing organosilica moieties into the framework of silica to fabricate biodegradable mesoporous silica nanoparticles (MSNs) with oxidative and redox dual-responsiveness is reported. These diselenide-bridged MSNs can encapsulate cytotoxic RNase A into the 8-10 nm internal pores via electrostatic interaction and release the payload via a matrix-degradation controlled mechanism upon exposure to oxidative or redox conditions. After surface cloaking with cancer-cell-derived membrane fragments, these bioinspired RNase A-loaded MSNs exhibit homologous targeting and immune-invasion characteristics inherited from the source cancer cells. The efficient in vitro and in vivo anti-cancer performance, which includes increased blood circulation time and enhanced tumor accumulation along with low toxicity, suggests that these cell-membrane-coated, dual-responsive degradable MSNs represent a promising platform for the delivery of bio-macromolecules such as protein and nucleic acid therapeutics.

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study

Abstract: Summary Background Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community. Cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, is an alternative to aspirin that works through a different mechanism. This trial aimed to compare the efficacy and safety of cilostazol with that of aspirin for the long-term prevention of the recurrence of ischaemic stroke. Methods 720 patients (mean age 60·2 years, SD 9·86) who had had an ischaemic stroke within the previous 1–6 months were enrolled consecutively in a prospective, multicentre, double-blind, randomised trial. 360 patients were randomly assigned to receive cilostazol and 360 patients to receive aspirin. Analysis was by intention to treat. Patients in both groups took the medication for 12–18 months. The primary endpoint was any recurrence of stroke (ischaemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage) during the trial period. All patients had MRI with T1 MRI, T2 MRI, diffusion-weighted imaging (DWI), T2 fluid-attenuated inversion recovery (FLAIR), and T2 gradient echo imaging (T2*) at the beginning and the end of the study. This trial is registered with ClinicalTrials.gov, number NCT00202020. Findings The average duration of treatment was 740 person-years, and 719 patients were analysed (360 in the cilostazol group and 359 in the aspirin group). The primary endpoint was reported in 12 patients in the cilostazol group and in 20 patients in the aspirin group. The estimated hazard ratio, calculated with Kaplan–Meier curves (risk of primary endpoint in cilostazol group vs aspirin group), was 0·62 (95% CI 0·30–1·26; p=0·185). Symptomatic cerebral haemorrhage was reported in six patients: one in the cilostazol group and five in the aspirin group. Asymptomatic cerebral haematoma was found in four patients in the aspirin group and one patient in the cilostazol group. Brain bleeding events were significantly more common in the aspirin group than in the cilostazol group (7 vs 1, p=0·034). All of the six patients with symptomatic haemorrhage had previous cerebral microbleeds in the area where the haematoma was located. Interpretation The results of this pilot study showed no significant difference in the rate of recurrence of stroke between patients with ischaemic stroke who were randomly assigned to take either cilostazol or aspirin. The lower rates of ischaemic and haemorrhagic stroke in the cilostazol group suggest that cilostazol might be a more effective and safer alternative to aspirin for Chinese patients with ischaemic stroke; however, a larger phase III trial is required to confirm this. Funding National Health Ministry of the People's Republic of China; Otsuka Pharmaceutical.